Bruton tyrosine kinase inhibitors in B-cell lymphoma: beyond the antitumour effect

Bruton tyrosine kinase inhibitors in B-cell lymphoma: beyond the antitumour effect

Abstract Targeting B-cell receptor signalling using Bruton tyrosine kinase (BTK) inhibitors (BTKis) has become a highly successful treatment modality for B-cell malignancies, especially for chronic lymphocytic leukaemia. However, long-term administration of BTKis can be complicated by adverse on- an...

Full description

Bibliographic Details
Main Authors: Haoran Wang, Hao Guo, Jingyi Yang, Yanyan Liu, Xingchen Liu, Qing Zhang, Keshu Zhou
Format: Article
Language:English
Published: BMC 2022-09-01
Series:Experimental Hematology & Oncology
Subjects:
BTK inhibitors
B-cell lymphoma
Immunomodulation
Tumour microenvironment
Combination therapy
Infection
Online Access:https://doi.org/10.1186/s40164-022-00315-9

Internet

https://doi.org/10.1186/s40164-022-00315-9

Similar Items